Table 3 Summary clinical findings for meta-analysis and descriptive review cohorts
Meta-analysis (N = 14 studies) | ||||
|---|---|---|---|---|
Age (mean age ± SD) | Sex (F/M) | Disease type | ILD (fibrotic vs non-fibrotic) | Rationale for initiating RTX |
52 ± 7 | 184/77 (not delineated in two studies (N = 35)) | SSc = 120 RA = 98 ASS = 22 SS = 12 SLE = 7 IIM = 8 Unclassifiable = 4 | Fibrotic = 290* OP = 3 Nodular or GGO = 4 | Non-response to prior therapy = 260 Firstline = 3 Randomized = 33 |
Descriptive analysis (N = 6 studies) | ||||
|---|---|---|---|---|
Age (mean age) | Sex (F/M) | Disease type | ILD (fibrotic vs non-fibrotic) | Rationale for initiating RTX |
56 ± 3 | 41/34 (not delineated in one study (N = 31)) | SSc = 3 RA = 39 ASS = 52 IIM = 3 MCTD = 2 Unclassifiable = 1 | Fibrotic = 95* OP = 2 LIP = 1 Unclassified = 1 | Non-response to prior therapy = 62 Firstline = 7 (Not delineated in 2 studies (N = 38)) |